CTMXCytomX Therapeutics, Inc.
$2.19-48% 1Y
$2.19
$2.1252 weeks$6.75
The financials
CytomX Therapeutics, Inc. by the numbers
CytomX Therapeutics, Inc. (CTMX) reported revenue of $1.7M in Q3 2026 (quarter ended Sep 30, 2026), down 72% from the same quarter a year earlier. That came with net loss of $20M. For the full year FY2025, revenue was $76M (−45% year on year) with a net loss of $17M. The next results filing is expected around Feb 4, 2027, a quarter after the last one.
| Income statement | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $1.7M | $6.0M | −72% |
| Operating income | −$24M | −$16M | n/a |
| Net income | −$20M | −$14M | n/a |
| Diluted EPS | −$0.09 | −$0.09 | n/a |
Over its last three fiscal years CytomX Therapeutics, Inc. booked income tax of 23.8% of its pretax profit, above the 21.3% median for US companies in our tax study.
Biotechnology
The closest names by size in the same industry